LRRK2 inhibitors
The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
1. A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
R 1 is R 4 ;
R 2 is a C 1 -C 3 alkyl, an isotopically labelled C 1 -C 3 alkyl, a C 3 -C 6 cycloalkyl, or a C 1 -C 3 haloalkyl;
R 3 is halogen, cyano, a O-C 1 -C 3 haloalkyl, a C 1 -C 3 haloalkyl, a C 3 -C 6 cycloalkyl, or a C 1 -C 3 alkyl;
R 4 is a C 3 -C 6 cycloalkyl;
wherein each cycloalkyl is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of cyano, deuterium, halogen, C 1 -C 3 alkyl, an isotopically labelled C 1 -C 3 alkyl, a O-C 1 -C 3 haloalkyl, a O-C 1 -C 3 alkyl, and a C 1 -C 3 haloalkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from a C 1 -C 3 alkyl, an isotopically labelled C 1 -C 3 alkyl and a C 3 -C 6 cycloalkyl.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from —CH 3 , CH 2 CH 3 , —CD 3 and cyclopropyl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is an isotopically labelled C 1 -C 3 alkyl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —CD 3 .
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is chloro.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 3 .
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 2 CH 3 .
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is unsubstituted.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is substituted with 1 or 2 groups independently selected from the group consisting of cyano, halogen, and a O-C 1 -C 3 alkyl.
11. The compound of claim 1 , selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
12. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.